Literature DB >> 3072558

Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses.

H Möllmann1, P Rohdewald, J Barth, C Möllmann, M Verho, H Derendorf.   

Abstract

The pharmacokinetics of methylprednisolone and two methylprednisolone esters, the phosphate and the hemisuccinate, were investigated after intravenous administration of the esters to 12 healthy male subjects in two different doses (250 and 1000 mg). Methylprednisolone was formed more rapidly from phosphate than from hemisuccinate. During the first 30 min methylprednisolone levels were three to four times higher after phosphate administration than after hemisuccinate. The mean residence time of the hemisuccinate was significantly longer and the total-body clearance lower than those of the phosphate. Whereas very little of the phosphate (mean, 1.7%) was eliminated unchanged into the urine, there were significant amounts of hemisuccinate (mean, 14.7%) excreted renally and therefore not bioavailable. Methylprednisolone saliva levels paralleled plasma levels; the average saliva/plasma ratio was 0.22. Neither phosphate nor hemisuccinate could be detected in saliva. An average of 7.2% of the administered dose was eliminated in the form of methylprednisolone in urine. Renal clearance was 24 ml/min and not dose or prodrug dependent. For both doses endogenous hydrocortisone levels were lowered after 24 hr. For the 1000-mg dose the depression was still significant after 48 hr. The results indicate that methylprednisolone phosphate results in a faster and more efficient conversion to its active form, methylprednisolone, than methylprednisolone hemisuccinate.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3072558     DOI: 10.1023/a:1015921408870

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  6 in total

1.  Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration.

Authors:  P K Narang; R Wilder; D C Chatterji; R L Yeager; J F Gallelli
Journal:  Biopharm Drug Dispos       Date:  1983 Jul-Sep       Impact factor: 1.627

2.  HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids.

Authors:  H Derendorf; P Rohdewald; G Hochhaus; H Möllmann
Journal:  J Pharm Biomed Anal       Date:  1986       Impact factor: 3.935

3.  Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma.

Authors:  P Rohdewald; J Rehder; G Drehsen; G Hochhaus; H Derendorf; H Möllmann
Journal:  J Pharm Biomed Anal       Date:  1985       Impact factor: 3.935

4.  The clinical pharmacology of methylprednisolone sodium phosphate. I. Intramuscular route of administration.

Authors:  E Novak; A R DiSanto; C E Seckman; G Elliott; J G Lee; S S Stubbs
Journal:  J Clin Pharmacol       Date:  1977 May-Jun       Impact factor: 3.126

5.  Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults.

Authors:  S J Szefler; W F Ebling; J W Georgitis; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Kinetics of methylprednisolone and its hemisuccinate ester.

Authors:  H Derendorf; H Möllmann; P Rohdewald; J Rehder; E W Schmidt
Journal:  Clin Pharmacol Ther       Date:  1985-05       Impact factor: 6.875

  6 in total
  7 in total

Review 1.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 2.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 3.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  [Clinical experiences and results of high-dosage methylprednisolone therapy in spinal cord trauma 1991 to 1993].

Authors:  C Gäbler; R Maier
Journal:  Unfallchirurgie       Date:  1995-02

6.  High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response.

Authors:  P J Hayball; D G Cosh; M J Ahern; D W Schultz; P J Roberts-Thomson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs.

Authors:  A S Kearney; V J Stella
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.